-
新型冠状病毒(SARS-CoV-2)感染在武汉爆发后,WHO将这一病毒导致的疾病命名为COVID-19(coronavirus disease in 2019)。近期,在已发表的COVID-19研究病例中,除呼吸系统疾病外,还表现出各种程度的肝损伤临床特征[1-2]。2020年1月30日发表的文章指出[3],在99例COVID-19患者中,有43例患者出现了不同程度的肝功能异常。目前,对COVID-19引起患者肝功能异常的原因尚不清楚。本文从COVID-19患者肝功能异常为切入点,通过查阅相关文献报道,试图分析造成肝损伤的因素及机制,对已出现肝功能异常的COVID-19患者,如何用药及开展相应的药学监护提供参考。
HTML
[1] | PAN F, YE T H, SUN P, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia[J]. Radiology,2020,295(3):200370. |
[2] | DU Z W, WANG L, CAUCHEMEZ S, et al. Risk for transportation of 2019 Novel Coronavirus Disease from Wuhan to other cities in China[J]. Emerg Infect Dis,2020,26(5):1049-1052. |
[3] | CHEN N S, ZHOU M, DONG X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet,2020,395(10223):507-513. |
[4] | HUANG C L, WANG Y M, LI X W, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet,2020,395(10223):497-506. |
[5] | ICHIYAMA T, ISUMI H, OZAWA H, et al. Cerebrospinal fluid and serum levels of cytokines and soluble tumor necrosis factor receptor in influenza virus-associated encephalopathy[J]. Scand J Infect Dis,2003,35(1):59-61. |
[6] | 刘必成, 高月明. “细胞因子风暴综合征”如何识别和处理[N]. 健康报, 2020-02-20(008). |
[7] | JENNIFER R T, MARCUS J K, CAMERON P S, et al. Into the eye of the cytokine storm[J]. Microbiol Mol Biol Rev,2012,76(1):16. |
[8] | CHOUSTERMAN B G, SWIRSKI F K, WEBER G F. Cytokine storm and Sepsis disease pathogenesis[J]. Semin Immunopathol,2017,39(5):517-528. |
[9] | XU X W, WU X X, JIANG X G, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series[J]. BMJ,2020,368:m606. |
[10] | 张竞文, 胡欣, 金鹏飞. 新型冠状病毒引起的细胞因子风暴及其药物治疗[J]. 中国药学杂志, 2020, 55(5):333-336. |
[11] | 任越, 姚美村, 霍晓乾, 等. 抗新型冠状病毒方剂基于花生四烯酸代谢通路防治“细胞因子风暴”的研究[J]. 中国中药杂志, 2020, 45(6):1225-1231. |
[12] | 何黎黎, 龚普阳, 封玥, 等. 中药在抗新型冠状病毒肺炎(COVID-19)引起的细胞因子风暴中的应用分析[J/OL]. 中草药, 2020, [2020-03-03]. http://kns.cnki.net/kcms/detail/12.1108.R.20200302.0944.004.html. |
[13] | ZHANG Y L, JIANG C Y. Cytokine storms: the dominant hand in acute respiratory distress syndrome[J]. Life Sci(生命科学),2015,27(5):554-557. |
[14] | SHINYA K, GAO Y W, CILLONIZ C, et al. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque[J]. J Virol,2012,86(11):6055-6066. |
[15] | CHAI X, HU L, ZHANG Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection[J]. bioRxiv, (2020-02-15)[2020-01-13]. http://www.instrument.com.cn/download/shtml/932534.shtml. |
[16] | CHALASANI N, BONKOVSKY H L, FONTANA R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study[J]. Gastroenterology,2015,148(7):1340-1352. |
[17] | 宣自学, 张国兵, 叶晓兰, 等. 新型冠状病毒肺炎患者肝损的原因分析[J]. 中国药理学通报, 2020, 36(4):591-592. |
[18] | 陈丹龙, 杨芳, 罗志英, 等. 全球抗新型冠状病毒药物研发现状和瓶颈[J]. 中国药理学通报, 2020, 36(4):459-469. |
[19] | LAN N T N, THU N T N, BARRAIL-TRAN A, et al. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam[J]. PLoS One,2014,9(1):e84866. |
[20] | 杨瑾, 莫国栋, 卢志军, 等. 我院107例干扰素注射液不良反应特点分析[J]. 今日药学, 2017, 27(3):199-201. |
[21] | DYSON J K, HUTCHINSON J, HARRISON L, et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use[J]. J Hepatol,2016,64(1):234-238. |
[22] | 聂青和. 糖皮质激素在肝衰竭治疗中的地位[J]. 中华肝脏病杂志, 2012, 20(6):414-415. |
[23] | 聂青和. 肝衰竭综合治疗进展[J]. 实用肝脏病杂志, 2013, 16(1):17-19. |
[24] | COTTIN J, PIERRE S, PIZZOGLIO V, et al. Methylprednisolone-related liver injury: a descriptive study using the French pharmacovigilance database[J]. Clin Res Hepatol Gastroenterol,2020-pii:S2210-7401(19)30270-0. |
[25] | GALVAÑ V G, OLTRA M R, RUEDA D, et al. Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease[J]. Clin Rheumatol,2007,26(6):971-972. |
[26] | PATON N I, LEE L, XU Y, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial[J]. Lancet Infect Dis,2011,11(9):677-683. |
[27] | 孙蓉, 黄伟, 李素君, 等. 关于“柴胡劫肝阴”的源流发展与初步实验研究[J]. 中国药物警戒, 2009, 6(10):577-580. |
[28] | 孙蓉, 杨倩. 柴胡挥发油对大鼠肝能量代谢的影响[J]. 中国药理学与毒学杂志, 2011, 25(3):310-313. |
[29] | 孙蓉, 吕丽莉, 王丽, 等. 柴胡致大鼠肝毒性氧化损伤机制研究[J]. 中药药理与临床, 2009, 25(1):49-51. |
[30] | 张丽美, 鲍志烨, 黄幼异, 等. 半夏水提组分对小鼠肝毒性“量-时-毒”关系研究[J]. 中国药物警戒, 2011, 8(1):11-15. |
[31] | 黄伟, 张作平, 黄幼异, 等. 提取工艺对半夏急性毒性与相关物质基础含量的影响研究[J]. 中国药物警戒, 2010, 7(11):656-660. |
[32] | GEORGIOU M, SIANIDOU L, HATZIS T, et al. Hepatotoxicity due to Atractylis gummifera-L[J]. J Toxicol Clin Toxicol,1988,26(7):487-493. |
[33] | 中华医学感染病学分会. 肝脏炎症及其防治专家共识[J]. 中国实用内科杂志, 2014, 7(1):4-12. |
[34] | 褚扬, 周王谊, 吴江, 等. 新型冠状病毒肺炎治疗中应关注肝损伤及防治中药概述[J/OL]. 世界中医药. http://kns.cnki.net/kcms/detail/11.5529.R.20200221.0904.006.html. |
[35] | 缪晓辉. 抗结核化疗诱导药物性肝损伤的护肝治疗[J]. 中华结核和呼吸杂志, 2013, 36:729-731. |
[36] | WANG C Y, KAO T C, LO W H, et al. Glycyrrhizic acid and 18β-glycyrrhetinic acid modulate lipopolysaccharide-induced inflammatory response by suppression of NF-κB through PI3K p110δ and p110γ inhibitions[J]. J Agric Food Chem,2011,59(14):7726-7733. |
[37] | SCHROFELBAUER B, RAFFETSEDER J, HAUNER M, et al. Glycyrrhizin, the main active compound in liquorice, attenuates pro-inflammatory responses by interfering with membrane-dependent receptor signaling[J]. Biochem J,2009,421(3):473-482. |
[38] | CHEN H S, DU Q H. Potential natural compounds for preventing SARS-CoV-2 (2019-nCoV) infection[EB/OL]. 2020. DOI: 10.20944/preprints202001.0358.v3 |